Fig. 3: 3C-LNPs suppress tumor growth and development in an orthotopic glioblastoma model.
From: Gene Therapy with Enterovirus 3 C Protease: A Promising Strategy for Various Solid Tumors
a Timeline of tumor implantation and treatment schedule in the intracranial glioblastoma model. Mice with orthotopic U87 MG-luc tumors were intracranially administered 3C-LNPs (1.2 μg/week or 2.4 μg/week), 3 C(C147S)-LNPs (2.4 μg/week) or an equal volume of PBS. b and c Bioluminescence images of luciferase-expressing U87 MG-luc tumors obtained after 1, 2, 3, 4 and 5 weeks of treatment (n = 6 mice/group). The data are presented as the means ± SEMs. Statistical differences were assessed via mixed effects with the Dunnett multiple comparisons test. ****P < 0.0001, n.s.= not significant. d Survival was assessed in the U87 MG-luc orthotopic mouse model using the log-rank (Mantel–Cox) test (n = 6 mice/group). e Body weight changes in tumor-bearing mice (n = 6 mice/group). f Representative H&E staining of tumor tissues from tumor-bearing mice from 6 mice/group. Scale bar, 500 μm. g Timeline of the tumor vascular microcirculation monitoring test in orthotopic U87 MG-luc tumor-bearing mice treated with 3C-LNPs (2.4 μg/week for two weeks) or PBS. h Representative images of the functional vasculature of 3C-LNP-treated or PBS-treated tumors (n = 3 mice/group). Scale bar: 1 mm. The data are presented as the means ± SEMs. Statistical differences were assessed using a two-tailed unpaired t test. *P < 0.05, **P < 0.01, ****P < 0.0001, n.s.= not significant. Source data are provided as a Source Data file.
